Gyon Technologies Capital Management, LP - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 147 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.

Quarter-by-quarter ownership
Gyon Technologies Capital Management, LP ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2022$750,291
+143.6%
16,834
+53.7%
0.28%
+192.7%
Q3 2022$308,000
-17.9%
10,953
-21.3%
0.10%
-8.6%
Q2 2022$375,000
+4.5%
13,918
+31.9%
0.10%
-58.5%
Q1 2022$359,000
-49.5%
10,552
-42.6%
0.25%
+93.1%
Q4 2021$711,000
-63.2%
18,388
-48.6%
0.13%
-74.8%
Q3 2021$1,931,00035,7640.52%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2023
NameSharesValueWeighting ↓
ACUTA CAPITAL PARTNERS, LLC 1,017,524$20,961,0007.56%
Octagon Capital Advisors LP 561,398$11,565,0004.36%
COMMODORE CAPITAL LP 369,951$7,621,0003.04%
Opaleye Management Inc. 985,000$20,291,0002.98%
VR Adviser, LLC 1,240,610$25,557,0002.77%
TSP Capital Management Group, LLC 359,229$7,400,0002.61%
RTW INVESTMENTS, LP 3,908,947$80,524,0001.26%
Ghost Tree Capital, LLC 250,000$5,150,0001.21%
Tri Locum Partners LP 196,672$4,051,0001.00%
Redmile Group, LLC 3,387,788$69,788,0000.98%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders